What is Stratedigm?
Stratedigm, Inc. is a key player in the development and manufacturing of advanced flow cytometry systems. Their product portfolio includes benchtop flow cytometers, such as the S1000EON series, engineered for high sensitivity and resolution. These systems are designed to meet the diverse needs of research institutions and laboratories, offering customizable configurations, automation capabilities, and user-friendly software. Manufactured in Silicon Valley, Stratedigm emphasizes reliability, service, and future-proof technology with an Anti-Obsolescence Guarantee, solidifying its commitment to quality and innovation in the scientific instrumentation market.
How much funding has Stratedigm raised?
Stratedigm has raised a total of $92K across 1 funding round:
Debt
$92K
Debt (2021): $92K with participation from PPP
What's next for Stratedigm?
With the recent influx of substantial expansion capital, Stratedigm is poised for a significant phase of growth and market penetration. The company's Series B/C stage funding context suggests a strategic focus on scaling production, enhancing research and development efforts, and potentially expanding its global footprint. This investment will likely fuel advancements in their flow cytometry technology, enabling them to capture a larger share of the research and clinical laboratory market. Future developments may include new product iterations, strategic partnerships, and enhanced service offerings to support their growing customer base.
See full Stratedigm company page
